Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 1997

View Archived Issues

Teva receives FDA approval for antihypertensive generic

Orally active antiplatelet agents disclosed by Mitsui Toatsu

Merck KGaA prepares cardioprotective agents

PGE1 derivatives for peripheral circulatory disorders from Ono

Meiji Seika describes potent, broad-spectrum carbapenems

PLC-inhibitory peptides from Kyowa Hakko

Connaught prepares Bordetella vaccine

Alfacell elucidates action of Onconase

ACAT inhibitors from Nihon Nohyaku

Roche reveals cephalosporins

Princeton and Lilly disclose nonclassical antifolates

First launch for Lipobay

Endocrine tumor gene identified by NIH team

Yamanouchi describes potent and selective steroid 17,20 lyase inhibitor

BASF selects dual D4/5-HT2 antagonist for clinical development

FDA clears Epivir under traditional regulations; clinical benefit confirmed

ImmunoGen's novel anticancer agent eradicates a human cancer in mice

ProScript licenses cell cycle regulation technology from Harvard Medical School

Alza and SmithKline Beecham sign new agreement for Nicoderm

Astra Arcus develops selective CCK-A agonist with potential for obesity

U.S. patent approval for Theratechnologies' antisense therapy

Orally bioavailable cyclic HIV protease inhibitors with low potential for drug resistance

EntreMed produces recombinant Angiostatin

Pfizer discovers potent, selective beta3-adrenoceptor full agonist

Balanced ETA/ETB antagonist from Abbott

New selective estrogen receptor modulator from Lilly

ID Biomedical reports positive results for rapid test for VRE

AutoImmune freezes development of Myloral

Company Profile: DGI BioTechnologies

Company Profile: CDR Therapeutics

Gensia Sicor and Sankyo collaborate in diabetes research

Agouron and Nastech to develop common cold treatment

IVAX presents promising preclinical results with Elmiron

Isis Pharmaceuticals initiates phase III trials of its antisense drug for Crohn's disease